Celyad Oncology Net Tangible Assets

Celyad Oncology (CYAD) currently reports a net tangible assets of $3.3M as of June 2024. That compares with $1M in the prior-year period — up 220.4% year over year. Use the charts on this page to explore Celyad Oncology's net tangible assets history and peer comparisons.

Celyad Oncology's net tangible assets increased from $1M to $3.3M — a 220.4% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Celyad Oncology reported $3.3M in net tangible assets as of June 2024. That compares with $1M in the prior-year period — up 220.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $3.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Celyad Oncology, and consider following CYAD for alerts when major investors trade the stock.

Celyad Oncology is classified in the Healthcare sector. On net tangible assets, it currently shows $3.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYAD with unrelated industries.